Home › Osteosarcoma › Texas › Dallas
Osteosarcoma clinical trials in Dallas, TX
5 studies for Osteosarcoma are looking for participants at sites in and around Dallas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
RecruitingPhase 2
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
RecruitingPhase 1/2
- Children's Medical Center, Dallas
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RecruitingPhase 1/2
- Children's Medical Center, Dallas
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
RecruitingPhase 3
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RecruitingObservational study
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Osteosarcoma trials in other cities
- Memphis, TN10 studies
- St. Louis, MO10 studies
- Atlanta, GA10 studies
- Boston, MA9 studies
- Mountain View, CA8 studies
- Birmingham, AL7 studies
- Houston, TX7 studies
- Chicago, IL7 studies
- Los Angeles, CA7 studies
- New York City, NY6 studies
- Tampa, FL6 studies
- Washington, DC6 studies
Other studies in Dallas
- Breast Cancer55 studies
- Non-Small Cell Lung Cancer52 studies
- Heart Failure42 studies
- Metastatic Cancer42 studies
- Cancer (all types)37 studies
- Prostate Cancer36 studies
- Colorectal Cancer33 studies
- Obesity31 studies
- Ovarian Cancer28 studies
- Lung Cancer27 studies
- Bladder Cancer27 studies
- Endometrial Cancer24 studies
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.